RT Journal Article
SR Electronic
T1 Effectiveness of training general practitioners in the ABC versus 5As method of delivering brief stop-smoking advice: a pragmatic, two-arm cluster randomised controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.26.20041491
DO 10.1101/2020.03.26.20041491
A1 Sabrina Kastaun
A1 Verena Leve
A1 Jaqueline Hildebrandt
A1 Christian Funke
A1 Stephanie Klosterhalfen
A1 Diana Lubisch
A1 Olaf Reddemann
A1 Hayden McRobbie
A1 Tobias Raupach
A1 Robert West
A1 Stefan Wilm
A1 Wolfgang Viechtbauer
A1 Daniel Kotz
YR 2020
UL http://medrxiv.org/content/early/2020/04/20/2020.03.26.20041491.abstract
AB OBJECTIVE To assess the effectiveness of a 3.5h-training for general practitioners (GPs) in two different methods (ABC, 5As) of giving brief stop-smoking advice during routine consultations.DESIGN Pragmatic two-arm cluster randomised controlled trial with pre-post-design for the primary outcome and cluster randomisation for secondary outcomes.SETTING General practices, North Rhine-Westphalia (German federal state), recruited 2017-2019.PARTICIPANTS Practices were randomised (1:1) to an ABC or 5As training. Tobacco smoking, adult patients, who consulted trained GPs in these practices in the 6 weeks prior to or following the training were eligible to participate. Ineligible were: non-smokers, patients who did not meet the GP in person, or could not provide informed consent.INTERVENTIONS Two different standardised 3.5h-trainings (ABC or 5As) for GPs in delivering brief stop-smoking advice were carried out per study cycle (six cycles in total). Trainings were moderated by a senior researcher and an experienced GP, and included role-plays with professional actors.MAIN OUTCOME MEASURES Primary outcome: patient-reported rates of GP-delivered stop-smoking advice prior and following the training, irrespective of the training method. Secondary outcomes: patient-reported receipt of recommendation/prescription of evidence-based smoking cessation treatment: including behavioural support, any pharmacotherapy (nicotine replacement therapy (NRT), varenicline, or bupropion), or a combination therapy; and the effectiveness of ABC versus 5As regarding all outcomes.RANDOMISATION AND MASKING Computer-generated block randomisation or, if not feasible, randomisation based on the GPs’ temporal availability at training dates. GPs were not fully blinded. Patients were blinded to the nature of the study until data collection ended.RESULTS 52 GP practices (27 ABC, 25 5As) with 69 GPs were included. Of 5,406 patients who provided informed consent, 1,937 (35.9%) were current smokers, of whom 1,039 were interviewed prior to and 898 following the training. GP-delivered stop-smoking advice increased from 13.1% (n=136/1,039) to 33.1% (n=297/898) following the training (adjusted odds ratio (aOR)=3.25, 95%CI=2.34 to 4.51). Recommendation/prescription rates of treatment were low (<2%) pre-training, but had increased after the training (e.g., behavioural support: aOR=7.15, 95%CI=4.02 to 12.74; any pharmacotherapy: aOR=7.99, 95%CI=4.11 to 15.52). GP-delivered stop-smoking advice increased non-significantly (p=0.08) stronger in the ABC vs. 5As group (aOR=1.71, 95%CI=0.94 to 3.12).CONCLUSIONS In GPs in Germany, a single session of training in stop-smoking advice was associated with a three-fold increase in rates of advice giving and a seven-fold increase in offer of support. The ABC method may lead to higher rates of GP-delivered stop-smoking advice during routine consultations. Approaches to further increase the delivery of such advice, and upscaling implementation strategies for the training in general practice, should be evaluated.TRIAL REGISTRATION German Clinical Trials Register: DRKS00012786.WHAT IS ALREADY KNOWN ON THIS TOPICThe implementation of clinical guideline recommendations stating that general practitioners (GPs) should routinely deliver brief stop-smoking advice and offer evidence-based smoking cessation treatment is low in Germany, a country with a smoking prevalence of ∼28%.A strategy is needed to overcome barriers (e.g., lack in knowledge and skills) preventing GPs from routinely delivering stop-smoking advice. No experimental study has evaluated such a strategy in German general practice so far.Two different methods of delivering such advice are recommended in the national guidelines – ABC and 5As – but it is unclear which method can be more effectively implemented by trained GPs.WHAT THIS STUDY ADDSThis cluster randomised controlled trial evaluated the effectiveness of a 3.5h-training for GPs in delivering brief stop-smoking advice and compared two different methods (ABC vs. 5As) regarding the rates of delivery of such advice and recommendations of evidence-based cessation treatment in 1,937 smoking patients from 52 GP practices in Germany.The training, irrespective of the method, was associated with a three-fold increase in rates of advice giving and a seven-fold increase in the offer of support.The data indicate that training according to ABC may be more effective than 5As in increasing the rates of GP-delivered stop-smoking advice.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work other than the governmental funding source (see funding statment); DK received an unrestricted grant from Pfizer for an investigator-initiated trial on the effectiveness of practice nurse counselling and varenicline for smoking cessation in primary care in 2009 (Dutch Trial Register NTR3067). HM has received honoraria for speaking at smoking cessation meetings and attending advisory board meetings that have been organised by Pfizer and Johnson & Johnson, TR has received honoraria from Pfizer, Novartis, Glaxo Smith Kline, Astra Zeneca and Roche as a speaker in activities related to continuing medical education and financial support for investigator-initiated trials from Pfizer and Johnson & Johnson, RW has undertaken research and consultancy for companies that develop and manufacture smoking cessation medications (Pfizer, Johnsons & Johnson, and Glaxo Smith Kline) and is an advisor to the UK’s National Centre for Smoking Cessation and Training; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. Clinical TrialDRKS00012786Clinical Protocols https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-017-4328-2 Funding StatementThe study was funded by the German Federal Ministry of Health (grant number ZMVI1-2516DSM221, governmental funding) who had no involvement in the design of the study, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this study are third-party data (de-identified participant data, syntax of statistical analyses) and are available to researchers on reasonable request from the corresponding author (sabrina.kastaun@med.uni-duesseldorf.de). All proposals requesting data access will need to specify how it is planned to use the data, and all proposals will need approval of the trial co-investigator team before data release.5AAsk, advice, assess, assist, arrangeABCAsk, brief advice, cessation supportBCTBehaviour Change TechniquesCIConfidence IntervalCOM-BCapability-Opportunity-Motivation-BehaviourFCTCFramework Convention on Tobacco ControlGPsGeneral practitionerHHUHeinrich-Heine UniversityMTSSMotivation to Stop ScaleNRTNicotine replacement therapySDStandard deviationSUTSStrength of Urges to Smoke Scale